See every side of every news story
Get Started
SubscribeLogin
Everton
Donald Trump
Ukraine War
Volodymyr Zelenskyy
Viktor Orbán
Hamas
Basketball
Israel-Hamas Conflict
Manchester United
Elon Musk
Premier League
Soccer
Published • loading... • Updated

Outer Cape Prepares for Federal Ruling on HIV Prevention Meds - The Provincetown Independent

Summary by The Provincetown Independent
PROVINCETOWN — When Jeff Schaffer learned in January that the Supreme Court would hear a case that threatened coverage of lifesaving HIV-prevention medications, he was not surprised. Members of the testNtreat team at OCHS in Provincetown: Alex Juchniewich, community health worker; Jeff Schaffer, founder and registered nurse; and LaKia Doncheva, community health worker and medical assistant. (Photo by Emily Schiffer) Schaffer, a registered nurse …

8 Articles

All
Left
2
Center
2
Right
1
The Provincetown IndependentThe Provincetown Independent

Outer Cape Prepares for Federal Ruling on HIV Prevention Meds - The Provincetown Independent

PROVINCETOWN — When Jeff Schaffer learned in January that the Supreme Court would hear a case that threatened coverage of lifesaving HIV-prevention medications, he was not surprised. Members of the testNtreat team at OCHS in Provincetown: Alex Juchniewich, community health worker; Jeff Schaffer, founder and registered nurse; and LaKia Doncheva, community health worker and medical assistant. (Photo by Emily Schiffer) Schaffer, a registered nurse …

Read Full Article
meaws.commeaws.com

FDA accepts Gilead’s new drug applications for lencapavir

Gilead pharmaceutical company announced today (Tuesday, Feb. 18) that the U.S. Food and Drug Administration has accepted the company’s  “new drug applications” for lencapavir, a twice-yearly injectable HIV-1 capsid inhibitor as a PrEP medication. Dietmar Berger, MD, PhD, chief medical officer for Gilead Sciences, said in a written statement that this approval brings the company “one step closer to introducing the first-ever twice-yearly HIV prev…

Read Full Article
Dallas VoiceDallas Voice

FDA accepts Gilead's new drug applications for lencapavir - Dallas Voice

Gilead pharmaceutical company announced today (Tuesday, Feb. 18) that the U.S. Food and Drug Administration has accepted the company’s  “new drug applications” for lencapavir, a twice-yearly injectable HIV-1 capsid inhibitor as a PrEP medication. Dietmar Berger, MD, PhD, chief medical officer for Gilead Sciences, said in a written statement that this approval brings the company  “one step closer to introducing the first-ever twice-yearly HIV pre…

Read Full Article
QuartzQuartz
Reposted by
DNyuzDNyuz

The FDA could approve a new twice-yearly HIV prevention treatment this year

Gilead said the FDA is reviewing its experimental twice-yearly injectable drug designed to prevent HIV

·United States
Read Full Article
European Medical JournalEuropean Medical Journal

Twice-Yearly HIV Prevention Shot Nears FDA Decision

The FDA has accepted a priority review of a new biannual HIV prevention injection, with a decision expected by June 19, 2025. Learn about its potential impact.

Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com

Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use - Pharmaceutical Technology

The FDA has accepted Gilead’s new drug application with a decision expected by 19 June 2025.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 40% of the sources lean Left, 40% of the sources are Center
40% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Quartz broke the news in United States on Tuesday, February 18, 2025.
Sources are mostly out of (0)

Similar News Topics

HIV

HIV

Pharma

Pharma

United States

United States

News
For You
Search
BlindspotLocal